Hormone therapy use, duration not tied to brain tumor risk for menopausal women

Among menopausal women, hormone therapy use and duration were not associated with brain malignancy risk, although researchers cautioned that more research is needed, according to findings published in Menopause.“The widespread use of HT is evident, with an estimated 600 million woman-years of HT usage recorded in Western countries over the past 50 years, beginning in 1970. As a result, a thorough understanding of the therapeutic benefits of HT in comparison to its potential risks is crucial for optimizing clinical decision-making and enhancing women’s health outcomes,” JinyuRead More